Hemophilia B replacement therapy drugs / 生物工程学报
Chinese Journal of Biotechnology
; (12): 164-171, 2016.
Article
en Zh
| WPRIM
| ID: wpr-242304
Biblioteca responsable:
WPRO
ABSTRACT
Hemophilia B is an X chromosome linked hereditary hemorrhagic disease, which is caused by the lose function mutation of factor IX (FIX), and significantly affects the patients' lifespan and life quality. The severity of hemophilia B depends on the FIX level in the plasma. By referring to the relevant literatures, we reviewed and summarized hemophilia B replacement therapies. Specifically, we focus on recombinant factor IX products on the market and those in the pipeline, especially on the long-acting factor IX drugs, to provide the basis for researches of new hemophilia B drugs.
Texto completo:
1
Índice:
WPRIM
Asunto principal:
Proteínas Recombinantes
/
Factor IX
/
Hemofilia B
/
Usos Terapéuticos
/
Quimioterapia
/
Genética
/
Mutación
Límite:
Humans
Idioma:
Zh
Revista:
Chinese Journal of Biotechnology
Año:
2016
Tipo del documento:
Article